Pear Therapeutics
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics.
We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.
Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions.
Our first product, reSET®, treats Substance Use Disorder and was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease.
Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, received marketing clearance from the FDA in December 2018.
Pear’s third PDT, Somryst®, is the first FDA-authorized prescription digital therapeutic (PDT) for patients with chronic insomnia and the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.
Pear’s cross-functional program teams work together to advance PDT and platform offerings from concepting through commercialization.
Program leads work with cross-functional leadership to oversee integrated product/clinical development and business strategy execution for each offering throughout its lifecycle; each program team is responsible for maximizing the value of its asset.
Program teams bring together leaders from Product Development, Commercial, Clinical/Medical/ Regulatory/Quality and G&A.
The Program and Portfolio Management team reports to the VP of Portfolio Management, in the product development organization: close alignment between each program and product development leadership is critical to continued innovation.
In addition to overseeing programs from Discovery through Commercialization, the team is also responsible for strategic planning and portfolio management, supporting effective decision making across Pear through quantitative and qualitative analysis.
Lastly, the team is responsible for the evolution of Pear’s Therapeutic Development Process (TDP), which blends the traditional R&D processes seen in biopharma, with best practices in medical device controls and agile software development processes that embrace continuous learning/iteration and user-centered design.
What you’ll do
The Director, Strategic Program Management will serve as the cross-functional leader of a range of strategic initiatives ranging from new pipeline programs (straddling the intersection of product and clinical development) to launch excellence to the evolution of our technical assets.
Responsibilities include:
This involves five core responsibilities:
What you have
Ideal candidates will have independently driven high-stakes development projects to completion in other organizations
Ideally, experience in advancing a therapeutic or medical device through a development process that involves coordinating multiple functions
Skills & Approach
advocating for any one activity or department
Equal Employment Opportunity:
Pear Therapeutics is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion or religious creed, ancestry, age, sex (including pregnancy, childbirth, breastfeeding and related medical conditions), sexual orientation, gender identity or gender expression, national origin, genetic information, qualified physical or mental disability or handicap, medical condition, qualified military or veteran status, or any other basis protected by applicable law.
Pear Therapeutics also follows all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act.
This policy applies to all terms and conditions of employment, including hiring, placement, promotion, termination, layoff, recall, transfers, leave of absences, compensation and training.